Biotest AG — Investor Presentation 2011

Jun 21, 2011

Disclaimer

• • This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and thus are subject to risks and elements of uncertainty that could result in deviation of actual developments from expected developments.
• • The forward forward-looking statements are only valid at the time of publication Biotest does looking publication. not intend to update the forward-looking statements and assumes no obligation to do so.

Big Success for Biotest's Biotherapeutics:

Biotest and Abbott signed a

"Licence, Development , and Commercialization Agreement"

to ensure the further development as well as later on production and worldwide marketing and sales of BT-061

Company Presentation June 2011 Biotest AG 2

Biotest and Abbott Global Agreement towards BT-061

• •Biotest receives upfront payment of USD 85 million
• • Biotest will be eligible to milestone payments pending completion of certain development regulatory commercial and sales milestones development, regulatory, milestones
• •Total Potential Milestone Payments USD 395 million
• •Total Deal Value: USD 480 million
• •Biotest will receive royalty payments on net sales achieved outside Europe EU51)
• •For Europe EU5 cost/profit split agreed

•Partnership Structure

• •Joint development by Biotest and Abbott
• •Biotest to co co-promote BT promote BT-061 in Germany France United Kingdom Italy Spain 061 Germany, France, Kingdom, Italy, Spain
• •Abbott will have exclusive global rights to commercialize BT-061 outside the EU5
• •Biotest Pharmaceuticals Corp. to manufacture product for clinical trials
• •Abbott and Biotest will share responsibility for commercial production

1) Germany, France, United Kingdom, Italy, Spain

BT-061: Compound Specifics and Development Status

• •Monoclonal antibody that activates regulatory T cells
• •Humanization by CDR grafting
• •Non-depleting
• • Species specificity: binds only to a special epitope on human CD4
• •No activation of effector T cells
• • P i i ffi d f d f h II li i l Promising efficacy an d safety data of p hase II clinicaltrials in Rheumatoid Arthritis (RA) and Psoriasis (PS)
• •Phase II b trial in RA ongoing

BT-061 H th P t ti l 061 Has the Potentialt M di ll Diff ti t i to Medically Differentiate via Efficacy and Safety

• •G d f t fil ft t t t f 350 bj t Good safety profile after treatment of approx. 350 subjects
• •Efficacy observed in clinical trials compares favourable to approved drugs

Unique Mode of Action of BT-061: Comparison to Conventional CD4 mAbs

conventional anti CD4mAbs

			i l i i- C C D D 4 4 A b t t t c o n v e n o n a a a n n m s
		B T- 0 6 1	de le t ing p ( Hu M -C D 4 *) e. g. ax	de le ing t no n- p
D l i t e p e o n	A D C C	-	+	-
	C C D	-	/- +	-
B l k d f C D 4 f i t o c a e o u n c o n i d r e q u r e		-	-	+
A i i f T t t c v a o n o r e g s		+	-	-
A i i f T h l l l t t c v a o n o e p e r c e s		-	-	-
D i d f l i i l o s e s r e q u r e o r c n c a f f i ( i ) e c a c y v		h ig h f f ica lre dy e cy a a 1 0 0- 2 0 0 0 fo l d low t a er do ( 0. 2. iv ) 5 5 se s m g -	5 0 5 0 0 iv m g -	1 0 0 1 0 0 0 iv m g -
*) Str d e t a l. 2 00 7 a nd cite d t he rei an n				E f f ica t s f f ic ien t cy no u fo l in ica l s in r c uc ce ss to im d ise au mu ne as e

Market Environment in Rheumatoid Arthritis andPsoriasis

Rheumatoid Arthritis Market:1Continuous Growth until 2014 Driven by Biologics

Largest Products in RA in 2010 in MM7 1(bn US \$)

Rheumatoid Arthritis Product Sales Forecast for MM71 Patent Expiries after 2014 Generates Pressure on anti-TNFs

Company Presentation June 2011 Biotest AG

Rheumatoid Arthritis Product Sales Forecast for MM71 Innovative Products Needed in Rheumatoid Arthritis

Competitive Environment

• • Many candidates stopped within last two years due to lack of clear differentiation y pp y
• •Pipeline dominated by "me too" candidates
• • Only few innovative products in development, but required to further improve patient safety

Biotest's Biotherapeutics portfolio

Biotest : Future corporate structure

Biotest: a specialized pharmaceutical company

FY 2010

Thank you

for your attention!

Contact

I t n v e s o	G R l t i B i t t A r e a o n s o e s :
D M i k B t t k i t r. o n a e r e u f H d I t R l t i e a o n e s o r e a o n s v
P h o n e : F a x : E M i l a : -	4 9 ( 0 ) 6 6 1 1 0 0 3 3 8 0 1 4 4 0 6 + - - 4 9 ( 0 ) 6 1 0 3 8 0 1 3 4 7 + - - i l i @ b i d t t t t. n v e s o r_ r e a o n s o e s e